Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors
JCO Precision Oncology · 2025-12 · (9)
DOI: 10.1200/po-25-00176 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JCO Precision Oncology, 2025-12. Verfasst von Rebecca Hassoun und 22 weiteren Autor:innen. Beteiligte Einrichtung: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Neoplasms, Germ Cell and Embryonal, Neoplasm, Residual, Biomarkers, Tumor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Serum tumor markers (STMs), including alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG), are currently used in management of patients with germ cell tumors (GCTs). STMs in a substantial proportion of patients are normal or falsely elevated. We evaluated circulating tumor DNA (ctDNA) as a prognostic biomarker in patients with GCTs. PATIENTS AND METHODS Longitudinal ctDNA testing was performed on a multi-institutional cohort of patients with GCTs using a clinically validated, personalized, tumor-informed 16-plex multiplex PCR-NGS ctDNA assay (Signatera, Natera Inc). ctDNA was evaluated preorchiectomy and during the molecular residual disease (MRD; 1-12 weeks postorchiectomy) and surveillance windows (>12 weeks postorchiectomy, after retroperitoneal lymph node dissection [RPLND], or postchemotherapy). The correlation between ctDNA status and event-free survival (EFS) was assessed. RESULTS ctDNA testing was performed for 74 patients (324 plasma samples) with clinical stages I to III GCTs. The median age was 34 years (IQR, 27-39), and the median follow-up was 17 months (IQR, 12-25). Disease management postorchiectomy included surveillance in 23% (17/74), RPLND in 7% (5/74), chemotherapy in 41% (30/74), and chemotherapy + RPLND in 29% (22/74) of patients. Preorchiectomy ctDNA was detectable in 14 of 15 patients. During the MRD (N = 42) and surveillance (N = 51) windows, patients who were ctDNA-positive versus ctDNA-negative showed a significantly inferior EFS during MRD (hazard ratio [HR], 5.11 [95% CI, 1.31 to 19.95]; P = .019) and surveillance windows (HR, 12.45 [95% CI, 4.32 to 35.85]; P < .0001). By contrast, elevated versus normal STM was not associated significantly with worse EFS (MRD: HR, 2.97 [95% CI, 0.68 to 13.05]; P = .149. surveillance: HR, 1.74 [95% CI, 0.75 to 4.02]; P = .194). CONCLUSION Tumor-informed ctDNA analysis shows promise for MRD detection in patients with GCTs. With further study, ctDNA monitoring may be useful in clinical decision making. Larger prospective trials are planned to establish clinical utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN.
- Icahn School of Medicine at Mount Sinai New York, New York, NY.
- Natera, Inc, Austin, TX.
- Rush University Medical Center, Chicago, IL.
- City of Hope Comprehensive Cancer Center, Duarte, CA.
- Vanderbilt University Medical Center, Nashville, TN.
ORCID-Profile: Rebecca Hassoun, Reuben Ben-David, George Laliotis, Cherry Au, Clint Cary, Kevin Manage, Punashi Dutta, Neeraja Tillu, Jennifer King, Tanya Dorff, Adam C ElNaggar, Minetta C Liu, Alan Tan, Nabil Adra, Alexander Chehrazi-Raffle
Zitieren
APA
Hassoun, R., Ben-David, R., Sfakianos, J. P., Laliotis, G., Au, C., Cary, C., Masterson, T. A., Manage, K., Dutta, P., Tillu, N., Cumarasamy, S., King, J., Rich, J., Rock, A., Dorff, T., Patel, M., Sharma, S., ElNaggar, A. C., Liu, M. C., …, & Chehrazi-Raffle, A. (2025). Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors. JCO Precision Oncology. https://doi.org/10.1200/po-25-00176
Vancouver
Hassoun R, Ben-David R, Sfakianos JP, Laliotis G, Au C, Cary C, et al. Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors. JCO Precision Oncology. 2025. doi:10.1200/po-25-00176
BibTeX
@article{Hassoun2025,
author = {Hassoun, Rebecca and Ben-David, Reuben and Sfakianos, John P and Laliotis, George and Au, Cherry and Cary, Clint and Masterson, Timothy A and Manage, Kevin and Dutta, Punashi and Tillu, Neeraja and Cumarasamy, Shivaram and King, Jennifer and Rich, Jordan and Rock, Adam and Dorff, Tanya and Patel, Mukti and Sharma, Shruti and ElNaggar, Adam C and Liu, Minetta C and Tan, Alan and Einhorn, Lawrence H and Adra, Nabil and Chehrazi-Raffle, Alexander},
title = {Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors},
journal = {JCO Precision Oncology},
year = {2025},
number = {9},
doi = {10.1200/po-25-00176}
}
EUVIMED